Page 7 - 《中国药房》2025年3期

·指南与共识·

胃癌药物治疗专家共识
Δ

重庆市医学会肿瘤学分会化疗学组，重庆市医药生物技术协会肿瘤罕见病疑难病专委会

中图分类号 R979.1；R735.2 文献标志码 A 文章编号 1001-0408（2025）03-0257-12
DOI 10.6039/j.issn.1001-0408.2025.03.01

摘 要 目的 指导胃癌（GC）的临床治疗用药，提高患者生存率，改善患者生存质量，为临床医师治疗决策提供参考。方法 由重
庆大学附属肿瘤医院肿瘤内科专家组成员采用名义群体法共同讨论确定《胃癌药物治疗专家共识》编写大纲。编写组专家针对大
纲涉及内容进行系统检索、分析、归纳及总结，并根据我国现状、临床需求和研究证据初步拟定推荐建议。重庆市医学肿瘤学分会
化疗学组及重庆市医药生物技术协会肿瘤罕见病疑难病专委会专家经过多轮会议讨论，对推荐建议进行修订，以投票形式确定最
终共识内容和推荐等级。结果与结论 本共识内容包括胃癌的围手术期药物治疗、晚期转移性胃癌一线药物治疗、晚期转移性胃
癌二线药物治疗、晚期胃癌三线及三线以上药物治疗、胃癌腹膜转移的药物治疗。本共识的发布为我国医疗机构在胃癌的个体化
用药方面提供了规范化管理的建议，对提高胃癌的临床疗效、用药安全具有重要意义。
关键词 胃癌；抗肿瘤药物；化疗；免疫治疗；靶向治疗；手术；专家共识

Expert consensus on drug therapy for gastric cancer
Chemotherapy Group of the Chongqing Medical Oncology Branch， Special Committee on Rare and Difficult
Cancers of Chongqing Medicinal Biotech Association

ABSTRACT OBJECTIVE To guide the clinical medication of gastric cancer， enhance patients’ survival rates， improve

patients’ quality of life， and provide a reference for clinicians in making treatment decisions. METHODS The nominal group
method was employed， wherein members of the expert group from the Department of Oncology at Chongqing University Cancer
Hospital collaboratively discussed and established the outline for the preparation of the Expert Consensus on Drug Treatment of
Gastric Cancer. The writing team of experts systematically searched， analyzed， and summarized the relevant content outlined， as
well as formulated consensus statements based on the current situation in China， clinical needs， and research evidence. After
multiple rounds of meetings and discussions， the experts from the Chemotherapy Group of the Chongqing Medical Oncology
Branch and the Special Committee on Rare and Difficult Cancers of Chongqing Medical and Biotechnology Association revised the
recommendation and ultimately reached the consensus content and recommendation level through voting. RESULTS &
CONCLUSIONS This consensus encompasses perioperative drug therapy for gastric cancer， first-line drug therapy for advanced
metastatic gastric cancer， second-line drug therapy for advanced metastatic gastric cancer， third-line and subsequent drug therapies
for advanced gastric cancer， and drug therapy for peritoneal metastasis of gastric cancer. The release of this consensus offers
standardized management suggestions for the individualized medication of gastric cancer by medical institutions in China， which is
of great significance for enhancing the clinical efficacy and medication safety associated with gastric cancer treatment.
KEYWORDS gastric cancer； anti-tumor drug； chemotherapy； immunotherapy； targeted therapy； surgical operation； expert
consensus

胃癌（gastric cancer，GC）是全世界发病率较高的肿 人数和病死人数均居世界首位，分别约占 43.9% 和
[1]
[2]
瘤之一，患者的5年生存率仅约20% 。我国胃癌的发病 48.6% 。据 2019－2021 年中国肿瘤生存数据统计，我
国胃癌5年标化相对生存率为35.2% 。靶向、免疫治疗
[3]
Δ 基金项目 吴阶平医学基金会临床研究基金（No.320.6750.2022-
18-53）；重庆市中青年医学高端人才项目（No.渝卫人〔2023〕10号）；重 等新型治疗模式的出现，一定程度上改善了患者的预
庆市国家级杰出青年后备人才培养项目（No.渝卫人〔2024〕31号） 后。但由于胃癌异质性强、生物学行为差、整体预后不
＊第一作者 王江红：主任医师，硕士。研究方向：消化系统肿瘤。
良，因此，规范化药物治疗具有十分重要的作用。为提
E-mail：wjhwin16@163.com
高医务人员对胃癌的规范化用药，为临床医师提供指导
# 通信作者 李咏生：主任医师，博士。研究方向：肿瘤内科学。
E-mail：lys@cqu.edu.cn 性用药参考，进而延长患者生存时间，改善患者生存质

中国药房 2025年第36卷第3期 China Pharmacy 2025 Vol. 36 No. 3 · 257 ·